Hereditary Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We compared the gene expression profile of SFs from FM individuals with two distinct CDKN2A/p16 mutations (V126D-p16 and R87P-p16) with the gene expression profile of SFs from age-matched individuals without p16 mutations and with no family history of melanoma.
|
23371019 |
2013 |
Hereditary Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the high rate of p16 mutations in squamous cell carcinomas and the association of p16 with familial melanoma propose p16 as an ideal candidate gene predisposing to familial squamous cell carcinomas.
|
16857415 |
2006 |
Hereditary Melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Little is known about the correlation between the loss of p16 expression and tumor progression in familial melanoma; no systematic study has been conducted on p16 expression in melanocytic tumors from patients carrying germline CDKN2A mutations.
|
14745721 |
2004 |
Hereditary Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred.
|
15304098 |
2004 |
Hereditary Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The p16 gene is frequently mutated in a variety of somatic tumors, as well as in familial melanoma and familial pancreatic carcinoma.
|
12352668 |
2002 |
Hereditary Melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This initial genetic evidence was subsequently strengthened by numerous studies documenting p16 inactivation in kindreds with familial melanoma.
|
11237522 |
2001 |
Hereditary Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These recent advances open up the possibility of genetic testing for melanoma susceptibility in the setting of familial melanoma and suggest novel therapeutic strategies for melanoma based on gene therapy or small molecule mimicry targeted to the correction of defects in the p16 regulatory pathway.(J Am Acad Dermatol 2000;42:705-22.)
|
10775844 |
2000 |
Hereditary Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In summary, our results show frequent involvement of the p16 gene in familial melanoma and confirm the role of the CDK4 gene as a melanoma-predisposing gene.
|
9425228 |
1998 |
Hereditary Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The product of the p16/INK4a/CDKN2/MTS1 tumor-suppressor gene acts as a negative cell cycle regulator by inhibiting G1 cyclin-dependent kinases that phosphorylate the retinoblastoma protein. p16 is inactivated in a wide range of human malignancies, including familial melanoma.
|
9694617 |
1998 |
Hereditary Melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a CDK4 gene mutation, responsible for a functional resistance of CDK4 kinase to p16 inhibitory activity, has been described to occur in some cases of familial melanoma.
|
9036865 |
1997 |
Hereditary Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Germ-line mutations in the cyclin-dependent kinase (CDK) inhibitor p16 have been reported in a subset of melanoma pedigrees, but their prevalence is unknown in more common cases of familial melanoma that do not involve large families with multiple affected members.
|
8710906 |
1996 |
Hereditary Melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent work on the molecular genetics of familial melanoma has suggested that the p16 kinase inhibitor gene (CDKN2) is one of the genes causing familial melanoma.
|
8791272 |
1996 |
Hereditary Melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline p16 mutations in familial melanoma.
|
7987387 |
1994 |